ADVAXIS MOVES FORWARD WITH LISTERIA VACCINE DEVELOPMENT

Advaxis is moving ahead with treatments that could complement two upcoming preventative cervical cancer vaccines in an effort to save the lives of women who have already developed cervical cancer.

The first cancer patients to be treated with an engineered live Listeria vaccine were recently dosed in a Phase I/II clinical trial of Lovaxin C, a Listeria-based therapeutic cancer vaccine developed to treat cervical cancer.

This is the first human study by Advaxis in its proposed development of a new class of cancer therapies. The trial, taking place in Serbia, Israel and Mexico, will enroll 20 cervical cancer patients and is expected to last approximately six months.